Nomogram Based on Systemic Immune-Inflammation Index to Predict Overall Survival in Gastric Cancer Patients

Table 2

Baseline characteristics for patients with versus in primary and validation cohorts.

Clinical parameter	Primary cohort				Validation cohort
	(356)	(332)			(90)	(84)
Sex			0.75	0.386			0.07	0.79
Male	249	222			67	64
Female	107	110			23	20
Age			0.55	0.457			0.01	0.932
≤60	235	228			53	50
>60	121	104			37	34
Tumor location			16.51	<0.001			1.35	0.51
Upper	36	70			17	11
Middle	142	125			25	28
Lower	178	137			48	45
Histological grade			31.85	<0.001			8.10	0.004
Well or moderately differentiated	153	214			61	39
Poorly or not differentiated	203	118			29	45
Lauren type			2.15	0.341			3.05	0.218
Diffuse	65	50			17	17
Intestinal	161	167			34	41
Mixed	130	115			39	26
Tumor size			55.11	<0.001			13.50	<0.001
≤5	212	104			45	27
>5	144	228			35	67
Lymphovascular invasion			1.39	0.238			0.02	0.896
No	257	226			57	54
Yes	99	106			33	30
Perineural invasion			6.20	0.013			0.09	0.766
No	219	173			64	58
Yes	137	159			26	26
TNM stage (AJCC, 8th)			83.59	<0.001			13.99	0.001
I	119	64			26	17
II	146	69			35	53
III	91	199			9	34
Adjuvant chemotherapy			0.84	0.36			1.55	0.213
No	144	123			36	26
Yes	212	209			54	58
NLR			140.83	<0.001			48.38	<0.001
	268	100			51	6
	88	232			39	78
PLR			123.64	<0.001			103.24	<0.001
	212	60			82	12
	144	272			8	72
MLR			38.74	<0.001			21.60	<0.001
	226	132			78	46
	130	200			12	38